Cerus

The installed base + consumable kits model will sustain revenue growth and produce recurring, higher‑margin revenue as units are adopted across blood centers and hospitals. If true, recurring consumable sales provide predictable revenue, margin uplift and operating leverage; if false, revenue will be lumpy and growth dependent on one‑time instrument sales.

Regulatory approval of the red blood cell INTERCEPT system (CE/FDA) is a required step to materially expand the addressable market and drive a step‑change in consumable revenue growth. A successful approval converts R&D investment into new recurring consumable sales across red blood cell transfusions; failure or long delays keep growth limited to platelets/plasma and compress the valuation upside.

As the installed base and consumable mix scale, fixed costs and prior R&D are absorbed and operating leverage should push operating losses toward breakeven and then to operating profits. Operating leverage turning on is the mechanism that converts top‑line growth into EPS upside and justifies a premium multiple; failure means growth without profits and likely dilution.

Current cash and modest positive operating cash flow provide a near‑term runway that reduces the immediate need for dilutive financing, assuming no major late‑stage trial or regulatory cost overrun. If the balance sheet can fund near‑term operations, management can focus on commercialization and regulatory milestones rather than capital raises that dilute shareholders; if not, dilution or distressed financing becomes likely.